Issues lobbied + lobbyists (6)
TRD — Trade (domestic/foreign)
Medical Device Safety Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Federal Procurement Preferences for Domestic Medicines Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
Government entities lobbied: Commerce, Dept of (DOC); Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); White House Office
MMM — Medicare/Medicaid
CMS Preference for Domestic Essential Medicines Net Elective Cost Policy: PBM Reform Through Bid Transparency
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); SENATE; White House Office
HCR — Health Issues
S. 2276/H.R. 3269: Eliminating Thickets to Increase Competition (ETHIC) Act S. 2296: National Defense Authorization Act (NDAA) for Fiscal Year 2026 Biosimilar Tariffs and USPTO Proposed Rule PTAB Proposed Rule - Restrict Use of IPR Medical Device Safety FDA Streamlining FY27 Appropriations: Domestic Production of Essential Medicines; Chemical-free Medical Devices Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining FY27 National Defense Authorization Act - Domestic Production of Essential Medicines CMS Preference for Domestic Essential Medicines Federal Procurement Preferences for Domestic Medicines Ancillary Product Patent Reform Net Elective Cost Policy: PBM Reform Through Bid Transparency Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC) Procurement
Government entities lobbied: Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Labor, Dept of (DOL); Natl Economic Council (NEC); Patent & Trademark Office (PTO); SENATE; U.S. Trade Representative (USTR); Veterans Affairs, Dept of (VA); White House Office
MAN — Manufacturing
Domestic Manufacturing CMS Preference for Domestic Essential Medicines Biopharmaceutical Manufacturing Preparedness Consortium (BioMaP) Industrial Base Management and Supply Chain (IBMSC)
Government entities lobbied: Commerce, Dept of (DOC); Defense, Dept of (DOD); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; Natl Economic Council (NEC); SENATE; White House Office
CPT — Copyright/Patent/Trademark
PTAB Proposed Rule - Restrict Use of IPR Patent Legislation Ancillary Product Patent Reform Clinical Trials for Biosimilars; Interchangeability Biosimilar Market Entry through Regulatory Streamlining
Government entities lobbied: Commerce, Dept of (DOC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; Patent & Trademark Office (PTO); SENATE; U.S. Trade Representative (USTR)
TAX — Taxation/Internal Revenue Code
Tax Incentives for Domestic Manufacturing Tax Credits for Domestic Manufacturing of Essential Medicines
Government entities lobbied: HOUSE OF REPRESENTATIVES; SENATE